Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care
The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce
This randomised, open-label, multi-centre trial assessed the efficacy and safety of the combination of Imfinzi (durvalumab) plus tremelimumab, as well as Imfinzi and tremelimumab monotherapies, versus standard-of-care chemotherapy
Zymeworks president & CEO Ali Tehrani said: “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and
Scientists have devised a new technique to 'decorate' gold nanoparticles with a protein of choice so they can be used to tailor drug to more accurately target an area
The settlement also resolves claims asserted by Dicerna in a lawsuit against Alnylam in the United States District Court for the District of Massachusetts. Each party has agreed
The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK. One of the current challenges
Helperby also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class
This investment brings the total Tmunity Series A financing to $135 million. Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell
The approval is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress. AstraZeneca oncology business unit
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.